Bladder News and Research

RSS

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).

29 Nov 2010

Less affluent cancer patients more likely to develop life-threatening health problems

CANCER patients from deprived backgrounds are more likely to develop life-threatening health problems, research published today (Wednesday) in the British Journal of Cancer shows.

24 Nov 2010

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

Engineers have developed a new type of microchip muscle stimulator implant that will enable people with paraplegia to exercise their paralysed leg muscles.

23 Nov 2010

Researcher develops new method that causes cancer cells to self-destruct

Tulane University researcher W T. Godbey has developed a treatment for cancer using a method that causes cancer cells to self-destruct while sparing surrounding healthy cells.

23 Nov 2010

BioCancell raises $5.1 million by excess demand in public offering

Success for BioCancell Therapeutics Inc. Excess demand in BioCancell's public offering of shares and warrants generated immediate proceeds of $5.1 million, 18% above its stated minimal fundraising goal of $4.3 million.

23 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

Palmetto GBA to cover PTNS therapy for patients with overactive bladder

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that Palmetto GBA for California, Nevada and Hawaii, a regional Medicare carrier, now covers posterior tibial nerve stimulation using the Urgent PC Neuromodulation System for the treatment of the symptoms of overactive bladder.

20 Nov 2010

Researchers develop medical model for regenerating bladders using stem cells

Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also represents another step towards new organ replacement therapies.

20 Nov 2010

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.

19 Nov 2010

FDA clears Multi-Lead Trialing Cable for SCS therapy

Medtronic Inc., the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy.

19 Nov 2010

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced achievement of a US$4.0 million milestone payment from its development partner, Endo Pharmaceuticals Inc. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009.

18 Nov 2010

BioSante announces sale of oncolytic virus technology to Cold Genesys

BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.

18 Nov 2010

Scientists determine ways to stop damage, promote neuronal growth in spinal cord injury

If researchers could determine how to send signals to cells responding to a spinal cord injury, they might be able to stop one type of cell from doing additional damage at the injury site and instead, coax it into helping nerve cells grow.

17 Nov 2010

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Tengion, Inc., a leader in regenerative medicine, announced today that the scheduled one-month, post-operative clinical assessment of the first implanted bladder cancer patient in its ongoing clinical trial has been completed as expected and has permitted the second patient to be enrolled without delay.

16 Nov 2010

Elderly often have poor outcomes from surgery: Study

A new study has shown the ill effects of surgery in the elderly. Results of the Australian study shows that one in five older patients will suffer complications from surgery and one in 20 will die within 30 days. Lead author and Associate Professor David Story from the University of Sydney and his team looked at more than 4,100 patients aged over 70 for the study.

11 Nov 2010

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2011 fiscal year (ended September 30, 2010).

10 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Bladder News and Research

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Less affluent cancer patients more likely to develop life-threatening health problems

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

Researcher develops new method that causes cancer cells to self-destruct

BioCancell raises $5.1 million by excess demand in public offering

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

Palmetto GBA to cover PTNS therapy for patients with overactive bladder

Researchers develop medical model for regenerating bladders using stem cells

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

FDA clears Multi-Lead Trialing Cable for SCS therapy

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

BioSante announces sale of oncolytic virus technology to Cold Genesys

Scientists determine ways to stop damage, promote neuronal growth in spinal cord injury

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Elderly often have poor outcomes from surgery: Study

Bioniche Life Sciences announces first quarter fiscal 2011 results

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News